M.D.
Radiation Oncologist
1981,M.D., Medicine, Johns Hopkins University, Baltimore, Maryland, Medicine
1982-1985, Radiation Oncology, University of California San Francisco, San Francisco, California
Jeffrey Y.C. Wong, M.D., is a professor of radiation oncology, professor of immunology and theranostics and the co-director of City of Hope® Duarte’s groundbreaking Center for Theranostic Studies.
With more than 25 years of experience at City of Hope alone, Dr. Wong has been instrumental in helping the institute’s Department of Radiation Oncology become one of the country’s most advanced, offering leading-edge treatments ranging from image-guided and intensity-modulated radiation therapy to TomoTherapy, CT simulation and advanced techniques like radioimmunotherapy and brachytherapy. As co-director of the Center for Theranostic Studies, Dr. Wong and his team work on advanced techniques that help physicians locate and treat cancer cells and tumors at the same time—an approach that’s changing how cancer care is delivered.
In his role as a radiation oncologist and physician-scientist, Dr. Wong focuses on developing new, more precise ways to deliver radiation treatment. He has helped create a targeted form of bone marrow radiation, treating the first patient in 2005 through a collaboration between the radiation team and bone marrow transplant specialists. He and his team have also pioneered a new method for total body irradiation (TBI) using image-guided and intensity-modulated radiation. This technique, called total marrow irradiation (TMI) or total marrow and lymphoid irradiation (TMLI), allows doctors to better target cancer while protecting healthy organs. City of Hope was the first in the world to use this approach in patients, and Dr. Wong’s team has shared their work with centers in Asia and Europe.
As co-director of the Center for Theranostic Studies, Dr. Wong continues to lead efforts in developing targeted treatments using radiopharmaceuticals—special drugs that carry radiation directly to cancer cells. He has led or co-led more than 20 clinical trials using these treatments for cancers of the colon, stomach, breast, lung and thyroid. His work helps bring promising new therapies from the lab directly to patients, offering more options and hope for the future.